Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/41901
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTrenson, Sander-
dc.contributor.authorVoros, Gabor-
dc.contributor.authorMARTENS, Pieter-
dc.contributor.authorIngelaere, Sebastian-
dc.contributor.authorBetschart, Pascal-
dc.contributor.authorVoigt, Jens-Uwe-
dc.contributor.authorDUPONT, Matthias-
dc.contributor.authorBreitenstein, Alexander-
dc.contributor.authorSteffel, Jan-
dc.contributor.authorWillems , Rik-
dc.contributor.authorRuschitzka, Frank-
dc.contributor.authorMULLENS, Wilfried-
dc.contributor.authorWinnik, Stephan-
dc.contributor.authorVandenberk, Bert-
dc.date.accessioned2023-12-01T12:26:27Z-
dc.date.available2023-12-01T12:26:27Z-
dc.date.issued2023-
dc.date.submitted2023-12-01T08:59:54Z-
dc.identifier.citationEUROPEAN JOURNAL OF HEART FAILURE,-
dc.identifier.urihttp://hdl.handle.net/1942/41901-
dc.description.abstractAim: Cardiac resynchronization therapy (CRT) is a cornerstone in the management of chronic heart failure in patients with a broad or paced QRS. However, data on long-term outcome after upgrade to CRT are scarce.Methods and results: This international, multicentre retrospective registry included 2275 patients who underwent a de novo or upgrade CRT implantation with a mean follow-up of 3.6 +/- 2.7 years. The primary composite endpoint included all-cause mortality, heart transplantation, or ventricular assist device implantation. The secondary endpoint was first heart failure admission. Multivariable Cox regression and propensity score matching (PSM) analyses were performed. Patients who underwent CRT upgrade (n = 605, 26.6%) were less likely female (19.7% vs. 28.8%, p < 0.001), more often had ischeemic cardiomyopathy (49.8% vs. 40.2%, p < 0.001), and had worse renal function (median estimated glomerular filtration rate 50.3 ml/min/1.73 m(2) [35.8-69.5] vs. 59.9 ml/min/1.73 m(2) [43.0-76.5], p < 0.001). The incidence rate of the composite endpoint was 10.8%/year after CRT upgrade versus 7.1%/year for de novo implantations (p < 0.001). PSM for the primary endpoint resulted in 488 pairs. After propensity score matching, upgrade to CRT was associated with a higher chance to reach the composite endpoint (multivariable hazard ratio [HR] 1.35, 95% confidence interval [CI] 1.08-1.70), for both upgrade from pacemaker (multivariable HR 1.33, 95% CI 1.03-1.70) and implantable cardioverter-defibrillator (ICD) (multivariable HR 1.40, 95% CI 1.01-1.95). PSM for the secondary endpoint resulted in 277 pairs. After PSM, upgrade to CRT was associated with a higher chance for heart failure admission (HR 1.74, 95% CI 1.26-2.41).Conclusion: In this retrospective analysis, the outcome of patients who underwent upgrades to CRT differed significantly from patients who underwent de novo CRT implantation, particularly for upgrades from ICD. Importantly, this difference in outcome does not imply a causal relation between therapy and outcome but rather a difference between two different patient populations.-
dc.description.sponsorshipBert Vandenberk, Pieter Martens, and Sander Trenson are supported by a research grant of the Frans Van de Werf Fund for Clinical Cardiovascular Research (Leuven, Belgium). Jens-Uwe Voigt hold a personal research mandate of the FWO (1832922N). Rik Willems is supported as postdoctoral clinical researcher by the Fund for Scientific Research Flanders. Conflict of interest: S.T. advisory board Medtronic, Vifor Pharma, AstraZeneca, Novartis; speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim and Novartis. J.S. consultant and/or speaker fees from Abbott, Alexion, AstraZeneca, Bayer, Berlin-Chemie, Biosense Webster, Biotronik, Boehringer Ingelheim, Boston Scientific, BMS, Daiichi Sankyo, Medscape, Medtronic, Menarini, Merck/MSD, Organon, Pfizer, Saja, Servier, and WebMD; ownership of Swiss EP and CorXL. R.W. research funding from Abbott, Biotronik, Boston Scientific, Medtronic; speakers and consultancy fees from Medtronic, Boston Scientific, Biotronik, Abbott. F.R. has not received personal payments by pharmaceutical companies or device manufacturers in the last 3 years (remuneration for the time spent in activities, such as participation as steering committee member of clinical trials and member of the Pfizer Research Award selection committee in Switzerland, were made directly to the University of Zurich). The Department of Cardiology (University Hospital of Zurich/University of Zurich) reports research, educational and/or travel grants from Abbott, Amgen, AstraZeneca, Bayer, Berlin Heart, B. Braun, Biosense Webster, Biosensors Europe AG, Biotronik, BMS, Boehringer Ingelheim, Boston Scientific, Bracco, Cardinal Health Switzerland, Corteria, Daiichi, Diatools AG, Edwards Lifesciences, Guidant Europe NV (BS), Hamilton Health Sciences, Kaneka Corporation, Kantar, Labormedizinisches Zentrum, Medtronic, MSD, Mundipharma Medical Company, Novartis, Novo Nordisk, Orion, Pfizer, Quintiles Switzerland Sarl, Sahajanand IN, Sanofi, Sarstedt AG, Servier, SIS Medical, SSS International Clinical Research, Terumo Deutschland, Trama Solutions, V- Wave, Vascular Medical, Vifor, Wissens Plus, ZOLL. The research and educational grants do not impact on F.R.’s personal remuneration. S.W. educational grant support and/or travel support and/or consulting/speaker fees from Abbott, Bayer, Biotronik, Boehringer Ingelheim, Boston Scientific, Cardinal Health, Daiichi-Sankyo, Fehling Instruments, Medtronic, and Servier. All other authors have nothing to disclose.-
dc.language.isoen-
dc.publisherWILEY-
dc.rights2023 European Society of Cardiology-
dc.subject.otherCardiac resynchronization therapy-
dc.subject.otherUpgrade-
dc.subject.otherHeart failure-
dc.subject.otherPacemaker-
dc.subject.otherImplantable cardioverter-defibrillator-
dc.titleLong-term outcome after upgrade to cardiac resynchronization therapy: A propensity score-matched analysis-
dc.typeJournal Contribution-
local.format.pages10-
local.bibliographicCitation.jcatA1-
dc.description.notesVandenberk, B (corresponding author), Katholieke Univ Leuven, Dept Cardiovasc Sci, Herestr 49, B-3000 Leuven, Belgium.-
dc.description.notesvandenberkbert@gmail.com-
local.publisher.place111 RIVER ST, HOBOKEN 07030-5774, NJ USA-
local.type.refereedRefereed-
local.type.specifiedArticle-
local.bibliographicCitation.statusEarly view-
dc.identifier.doi10.1002/ejhf.3073-
dc.identifier.pmid37905357-
dc.identifier.isi001103106000001-
local.provider.typewosris-
local.description.affiliation[Trenson, Sander; Voros, Gabor; Ingelaere, Sebastian; Voigt, Jens-Uwe; Willems, Rik; Vandenberk, Bert] Katholieke Univ Leuven, Dept Cardiovasc Sci, Herestr 49, B-3000 Leuven, Belgium.-
local.description.affiliation[Trenson, Sander] Sint Jan Hosp Bruges, Dept Cardiol, Brugge, Belgium.-
local.description.affiliation[Trenson, Sander; Betschart, Pascal; Breitenstein, Alexander; Steffel, Jan; Ruschitzka, Frank; Winnik, Stephan] Univ Hosp Zurich, Dept Cardiol, Zurich, Switzerland.-
local.description.affiliation[Trenson, Sander; Voros, Gabor; Voigt, Jens-Uwe; Willems, Rik; Vandenberk, Bert] Univ Hosp Leuven, Dept Cardiol, Leuven, Belgium.-
local.description.affiliation[Martens, Pieter; Dupont, Matthias; Mullens, Wilfried] Ziekenhuis Oost Limburg, Dept Cardiol, Genk, Belgium.-
local.description.affiliation[Mullens, Wilfried] Hasselt Univ, Dept Life Sci, Hasselt, Belgium.-
local.uhasselt.internationalno-
item.fullcitationTrenson, Sander; Voros, Gabor; MARTENS, Pieter; Ingelaere, Sebastian; Betschart, Pascal; Voigt, Jens-Uwe; DUPONT, Matthias; Breitenstein, Alexander; Steffel, Jan; Willems , Rik; Ruschitzka, Frank; MULLENS, Wilfried; Winnik, Stephan & Vandenberk, Bert (2023) Long-term outcome after upgrade to cardiac resynchronization therapy: A propensity score-matched analysis. In: EUROPEAN JOURNAL OF HEART FAILURE,.-
item.contributorTrenson, Sander-
item.contributorVoros, Gabor-
item.contributorMARTENS, Pieter-
item.contributorIngelaere, Sebastian-
item.contributorBetschart, Pascal-
item.contributorVoigt, Jens-Uwe-
item.contributorDUPONT, Matthias-
item.contributorBreitenstein, Alexander-
item.contributorSteffel, Jan-
item.contributorWillems , Rik-
item.contributorRuschitzka, Frank-
item.contributorMULLENS, Wilfried-
item.contributorWinnik, Stephan-
item.contributorVandenberk, Bert-
item.fulltextWith Fulltext-
item.accessRightsRestricted Access-
crisitem.journal.issn1388-9842-
crisitem.journal.eissn1879-0844-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
European J of Heart Fail - 2023 - Trenson - Long‐term outcome after upgrade to cardiac resynchronization therapy A.pdf
  Restricted Access
Early view1.05 MBAdobe PDFView/Open    Request a copy
Show simple item record

WEB OF SCIENCETM
Citations

2
checked on May 8, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.